KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Research & Development (2016 - 2025)

Historic Research & Development for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to $13.9 million.

  • Fulgent Genetics' Research & Development rose 1762.71% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.8 million, marking a year-over-year increase of 656.25%. This contributed to the annual value of $48.8 million for FY2024, which is 1779.92% up from last year.
  • As of Q3 2025, Fulgent Genetics' Research & Development stood at $13.9 million, which was up 1762.71% from $13.5 million recorded in Q2 2025.
  • Fulgent Genetics' Research & Development's 5-year high stood at $13.9 million during Q3 2025, with a 5-year trough of $5.3 million in Q2 2021.
  • In the last 5 years, Fulgent Genetics' Research & Development had a median value of $9.8 million in 2023 and averaged $9.6 million.
  • In the last 5 years, Fulgent Genetics' Research & Development surged by 18729.04% in 2021 and then fell by 4.45% in 2025.
  • Fulgent Genetics' Research & Development (Quarter) stood at $7.5 million in 2021, then increased by 14.0% to $8.5 million in 2022, then soared by 40.46% to $12.0 million in 2023, then increased by 1.35% to $12.1 million in 2024, then grew by 14.42% to $13.9 million in 2025.
  • Its Research & Development stands at $13.9 million for Q3 2025, versus $13.5 million for Q2 2025 and $12.4 million for Q1 2025.